Moxifloxacin Hikma (Moxifloxacin)

Moxifloxacin inhibits bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and transcription. By blocking these targets, the drug prevents bacterial DNA supercoiling and separation, leading to inhibition of cell division and bacterial death.

The dosing regimen for Moxifloxacin Hikma is determined by the prescribing clinician based on the type and severity of infection, patient weight, renal function, and other clinical factors. No fixed dose is provided here.

Safety data for Moxifloxacin during pregnancy and lactation are limited. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Moxifloxacin Hikma, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Moxifloxacin offers a broader spectrum against Gram‑positive organisms and enhanced activity against atypical pathogens compared with older fluoroquinolones such as ciprofloxacin. It also has a higher risk of QT‑interval prolongation, so cardiac monitoring may be more important when using moxifloxacin.

Store Moxifloxacin Hikma at ambient temperature, below 25 °C, in its original packaging. Protect the solution from light, moisture and extreme temperatures. Do not freeze. Follow standard aseptic techniques when preparing the intravenous infusion.

Moxifloxacin Hikma is administered by intravenous infusion. The solution is diluted in an appropriate compatible IV fluid and infused over the period recommended by the prescriber, typically 30–60 minutes, under aseptic conditions.

Serious adverse events include tendon rupture (especially Achilles), QT‑interval prolongation leading to arrhythmias, severe hypersensitivity reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, and rare but life‑threatening skin reactions like Stevens‑Johnson syndrome.

Moxifloxacin Hikma should be avoided in patients with known hypersensitivity to fluoroquinolones, a history of tendon disorders related to fluoroquinolone use, prolonged QT interval, or those taking other QT‑prolonging drugs without careful monitoring. It is also contraindicated in patients with severe renal impairment unless dose‑adjusted by a clinician.